factually
Index/Topics/ARIA Risk

ARIA Risk

The risk of Amyloid-Related Imaging Abnormalities (ARIA) associated with Donanemab and Lecanemab

Fact-Checks

2 results
Jan 14, 2026
Most Viewed

How do anti‑amyloid antibodies like lecanemab and donanemab differ in trial design, efficacy and safety outcomes for early AD?

Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...

Feb 7, 2026

Which patient subgroups (tau burden, APOE4 status, clinical stage) show the largest benefit from donanemab or lecanemab in trial subgroup analyses?

shows its clearest, largest subgroup benefit in patients with low-to-medium baseline burden (the “earlier” tau stage), with subgroup analyses reporting roughly one-third slower clinical decline and hi...